natgillin/translations-raw huggingface dataset:
Pulmonary adverse reactions (interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis) Haemoptysis 
Bolezni dihal, prsnega koša in mediastinalnega prostora sindrom akutne dihalne stiske pljučni neželeni učinki (intesticijska pljučnica, pljučni edem, pljučni infiltrati in pljučna fibroza) hemoptiza pljučna hemoragija
Unless your doctor directs you otherwise, you must stop breast-feeding if you use Grasustek. 
Če uporabljate zdravilo Grasustek, morate prenehati dojiti, razen če vam zdravnik ne naroči drugače.
The injections should be given into the thigh, abdomen or upper arm. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi
Uncommonly, cases have resulted in respiratory failure or ARDS, which may be fatal (see section 4.4). 
ARDS, ki sta lahko smrtno nevarna (glejte poglavje 4.4).
(VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils < 0.5 x 109) was observed in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and 12-21 years (6 days and 3.7 days, respectively) and adults. 
faze pri pediatričnih bolnikih s sarkomom (n = 37), ki so dobili 100 µg/kg pegfilgrastima po 1. ciklusu kemoterapije z vinkristinom, doksorubicinom in ciklofosfamidom (VAdriaC/IE), so pri mlajših otrocih, starih od 0-5 let, ugotovili dolgotrajnejšo hudo nevtropenijo (nevtrofilci < 0,5 × 109) (8,9 dneva) kot pri starejših otrocih, starih od 6-11 let (6 dni) in od 12-21 let (3,7 dneva), in pri odraslih.
Grasustek 6 mg solution for injection in a pre-filled syringe pegfilgrastim 
Grasustek 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi pegfilgrastim
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml (10 mg/ml) solution for injection. 
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml (10 mg/ml) raztopine za injiciranje.
The needle has flexible, rigid needle shield. 
Igla je zaščitena z upogljivim trdnim ščitnikom igle.
There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose. 
Pri potomcih brejih podgan, ki so jim subkutano dali pegfilgrastim, niso opazili neželenih učinkov, pri kuncih pa so pokazali, da pegfilgrastim v kumulativnih odmerkih, ki znašajo približno 4-kratni odmerek,
Uncommon events of cutaneous vasculitis have been reported in patients treated with pegfilgrastim. 
Občasno so pri bolnikih, ki so jih zdravili s pegfilgrastimom, poročali o dogodkih kožnega vaskulitisa.
Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration. 
Po dajanju G-CSF so poročali o neželenih učinkih na pljučih, zlasti o intersticijski pljučnici.
Water for injections 
polisorbat 20 voda za injekcije
Skin and subcutaneous tissue disorders 
Bolezni prebavil navzea1 Bolezni kože in podkožja
Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. 
Pri bolnikih, ki so prejemali filgrastim in pegfilgrastim, so poročali o primerih glomerulonefritisa.
USE OF THE MEDICINAL PRODUCT 
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR BLISTERED SYRINGE 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA BRIZGO V PRETISNEM OMOTU
Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. 
Po dajanju G-CSF zdravim osebam in onkološkim bolnikom so poročali o aortitisu.
PHARMACEUTICAL FORM AND CONTENTS Solution for injection in pre-filled syringe 1 pre-filled syringe with automatic needle guard (0.6 ml). 
Ena napolnjena injekcijska brizga z avtomatičnim ščitnikom igle (0,6 ml).
Injection site reactions, including injection site erythaema (uncommon) as well as injection site pain (common events) have occurred on initial or subsequent treatment with pegfilgrastim. 
Med začetnim ali nadaljnjim zdravljenjem s pegfilgrastimom so se pojavile reakcije na mestu injiciranja, vključno z eritemom na mestu injiciranja (občasno) in tudi bolečino na mestu injiciranja (pogosto).
Pulmonary adverse events 
Neželeni dogodki na pljučih
In a placebo-controlled, double blind study in patients with breast cancer the effect of pegfilgrastim on the incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimen associated with a febrile neutropenia rate of 10-20 % (docetaxel 100 mg/m2 every 3 weeks for 4 cycles). 
V dvojno slepi, s placebom kontrolirani študiji pri bolnicah z rakom na dojki so ocenili učinek pegfilgrastima na pojav febrilne nevtropenije po uporabi takšne sheme kemoterapije, ki je povezana z 10
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BLISTERED SYRINGE LABEL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
White blood cell (WBC) counts of 100 x 109/L or greater have been observed in less than 1 % of patients receiving pegfilgrastim. 
Pri manj kot 1 % bolnikov, ki dobivajo pegfilgrastim, so opazili število belih krvničk, ki je enako 100 × 109/l ali višje.
Common side effects (may affect up to 1 in 10 people) 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 oseb):
Croatia 
Magyarország
Hypersensitivity reactions; 
Bolezni imunskega sistema preobčutljivostne reakcije; anafilaksija
Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 ml solution for injection. 
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima* v 0,6 ml raztopine za injiciranje.
APPROPRIATE 
Pomembno
Vascular Disorders 
kožni vaskulitis
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution for injection. 
Ena napolnjena injekcijska brizga vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine za injiciranje.
Caution: Avoid contact with the plunger and needle during the preparation of the syringe, The safety device is normally activated by pressure from the plunger on the syringe. 
Varnostna naprava se običajno aktivira s pritiskom bata na brizgo.
Vertrieb 
Sledljivost
Inspect the medicine content through the viewing window of the pre-filled syringe. 
S pomočjo pregledovalnega okenca na napolnjeni injekcijski brizgi preglejte zdravilo.
Talk to your doctor, pharmacist or nurse before using Grasustek: 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Grasustek se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
The safety and efficacy of Grasustek have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression e.g., nitrosoureas. 
Pri bolnikih, ki prejemajo kemoterapijo, povezano z odloženo mielosupresijo, na primer nitrozouree,
Capillary leak syndrome1 
Bolezni živčevja glavobol1 Žilne bolezni sindrom kapilarne prepustnosti aortitis
After the injection is complete, one of the below alternatives can be followed : -Remove the needle from the injection site and release the plunger until the entire needle is covered by the guard. 
- Odstranite iglo z mesta injiciranja in sprostite bat, tako da varnostni ščitnik prekriva celotno iglo.
Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution. 
Ena napolnjena injekcijska igla vsebuje 6 mg pegfilgrastima v 0,6 ml raztopine.
România 
Bucharest, Romania
Immune system Disorders 
Organski sistem po MedDRA Neželeni učinki
How to store Grasustek 
Shranjevanje zdravila Grasustek
Shelf life 
USV Private Limited
Injection site pain Non-cardiac chest pain 
bolečina v prsih, ki ne izvira iz srca reakcije na mestu injiciranja
PHARMACEUTICAL FORM Solution for injection. 
raztopina za injiciranje v napolnjeni injekcijski brizgi
Keep pre-filled syringes out of the sight and reach of children. 
Napolnjene injekcijske brizge shranjujte nedosegljive otrokom.
This summary was last updated in May 2013. 
Ta povzetek je bil nazadnje posodobljen 05-2013.
The authorisation was renewed on 29 January 2006. 
Dovoljenje za promet z zdravilom je bilo podaljšano dne 29. januarja 2006.
Other information about Pirsue: 
Druge informacije o zdravilu Pirsue:
The clinical effectiveness was studied in a large number of dairy herds in 8 European countries. 
Klinično učinkovitost so preučili na velikem številu čred molznih krav v 8 evropskih državah.
The European Commission granted a marketing authorisation valid throughout the European Union, for Pirsue on 29 January 2001. 
Evropska komisija je dovoljenje za promet z zdravilom Pirsue, veljavno po vsej Evropski uniji, odobrila dne 29. januarja 2001.
Information was provided on the pharmaceutical quality, the tolerance of the product in cows and the safety in humans (people in contact with the product and consumers of meat and milk) and the environment. 
Predloženi so bili podatki o farmacevtski kakovosti, toleranci na zdravilo pri kravah ter njegovi varnosti za ljudi (za ljudi, ki pridejo v stik z zdravilom, in ljudi, ki uživajo meso in mleko) in okolje.
Pirlimycin hydrochloride 
Pirlimicin hidroklorid
As a result, the bacteria cannot produce any more protein and will stop growing. 
Zaradi tega bakterije ne morejo več tvoriti beljakovin in posledično se njihova rast prekine.
Cows with subclinically infected udders were treated with Pirsue (once daily for 8 days) or with another antibiotic, authorised in the EU to treat these infections. 
Krave s subklinično okužbo vimena so zdravili z zdravilom Pirsue (enkrat dnevno v trajanju 8 dni) ali z drugim antibiotikom, ki je dovoljen v EU za zdravljenje teh okužb.
Subclinical means that the infection is present but not sufficiently developed to produce clear clinical signs in the cow. 
Subklinična okužba pomeni, da je okužba že prisotna, vendar se še ni dovolj razvila, da bi se pri kravi pokazali jasni klinični znaki.
Mastitis is an infection in the udder. 
Mastitis je okužba vimena.
What is the risk associated with Pirsue? 
Kakšna tveganja so povezana z zdravilom Pirsue?
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. 
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) ocenil predloženo dokumentacijo, na podlagi česar je oblikoval priporočila glede uporabe zdravila.
Information on the prescription status of this product may be found on the label/outer package. 
Informacije o predpisovanju tega zdravila lahko najdete na notranji/zunanji ovojnini.
The benefit-risk balance may be found in module 6 of this EPAR. 
Razmerje med koristmi in tveganji je na voljo v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
Since milk is routinely checked for bacteria and other signs of infection, early stages of an udder infection in a dairy cow can easily be diagnosed. 
Ker se mleko redno preverja za vsebnost bakterij in druge znake okužbe, lahko pri molznih kravah z lahkoto odkrijemo zgodnje stopnje okužbe vimena.
What benefit has Pirsue shown during the studies? 
Kakšne koristi je zdravilo Pirsue izkazalo med raziskavami?
These infections were caused by incorrect administration of the product by the operator who, by inserting the syringe without adequate cleansing procedures, also inserted pathogenic (disease causing) bacteria from the environment into the udder. 
Te okužbe so bile posledice nepravilnega dajanja zdravila, pri čemer je oseba, ki je dajala zdravilo, vstavila brizgo brez primernega postopka čiščenja, zato je iz okolja v vime prenesla patogene bakterije (povzročitelje bolezni).
Milk samples were checked daily up to 30 days after treatment for bacteria and for other signs of infection. 
Vzorce mleka so vsak dan do 30. dne po končanem zdravljenju preverjali za vsebnost bakterij in druge znake okužbe.
Pirsue is generally well tolerated in cows. 
Krave na splošno dobro prenašajo zdravilo Pirsue.
Pirsue is given into each infected teat of the udder for 8 consecutive days. 
Zdravilo Pirsue dajemo v vsak okužen sesek 8 dni zapored.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)? 
Koliko časa mora preteči, preden se žival lahko zakolje in meso porabi za prehrano ljudi (obdobje karence)?
However, in rare cases, serious bacterial udder infections have occurred after treatment. 
Vendar so se v nekaterih redkih primerih po zdravljenju pojavile hude bakterijske okužbe vimena.
What is the time to allow before milk can be taken from the animal for human consumption? 
Koliko časa mora preteči, preden se lahko mleko uporabi za prehrano ljudi?
Why has Pirsue been approved? 
Zakaj je bilo zdravilo Pirsue odobreno?
In these studies, the effective concentration of pirlimycin required to stop bacterial growth was established. 
V teh raziskavah so določili učinkovito koncentracijo pirlimicina, ki je potrebna za zaustavitev rasti bakterij.
Pirsue is used in dairy cows to treat subclinical mastitis caused by specific groups of bacteria. 
Zdravilo Pirsue se uporablja za zdravljenje subkliničnega mastitisa pri molznih kravah, ki ga povzročajo posebne skupine bakterij.
It works by blocking the bacteria's ribosomes; this is the part of the cell where proteins are produced. 
Deluje tako, da blokira delovanje bakterijskih ribosomov, ki v celicah tvorijo beljakovine.
The field trial showed that treatment with Pirsue at the recommended dose was effective in the treatment of subclinical udder infections. 
Preskušanje na terenu je pokazalo, da je zdravljenje s priporočenim odmerkom zdravila Pirsue učinkovito pri zdravljenju subkliničnih okužb vimena.
Pirlimycin hydrochloride can cause severe eye and skin irritation. 
Pirlimicin hidroklorid močno draži oči in kožo.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Pirsue exceed the risks for the treatment of subclinical mastitis in lactating cows and recommended that Pirsue be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristni učinki zdravila Pirsue za zdravljenje subkliničnega mastitisa pri kravah v obdobju laktacije večji od z njim povezanih tveganj, zato priporoča odobritev dovoljenja za promet z zdravilom Pirsue.
Special care must, therefore, be taken by the operator not to introduce pathogens into the teat. 
To pomeni, da mora oseba, ki je daje zdravilo, biti posebno pozorna, da v sesek ne vnese patogenih organizmov.
The active substance in Pirsue is pirlimycin hydrochloride, an antibiotic of the lincosamide group. 
Zdravilna učinkovina zdravila Pirsue je pirlimicin hidroklorid, ki je antibiotik iz skupine linkozamidov.
What is Pirsue used for? 
Za kaj se zdravilo Pirsue uporablja?
It is given to dairy cows by infusion into the udder via the teat canal using a pre-filled syringe. 
Daje se molznim kravam v vime preko seskovega kanala z infuzijo s pomočjo napolnjene brizge.
How has Pirsue been studied? 
Kako je bilo zdravilo Pirsue raziskano?
The antimicrobial effectiveness of pirlimycin against different groups of bacteria causing disease in dairy cows was investigated in microbiological laboratories. 
V mikrobioloških laboratorijih so raziskali učinkovitost protimikrobnega delovanja pirlimicina proti različnim skupinam bakterij, ki povzročajo bolezen pri molznih kravah.
The results of these studies showed that Pirsue is effective at inhibiting the bacterial growth of a range of bacteria. 
Rezultati teh raziskav so pokazali, da zdravilo Pirsue učinkovito zavira rast določenih bakterij.
Pirsue is an antibiotic that contains pirlimycin hydrochloride as the active substance. 
Zdravilo Pirsue je antibiotik, ki vsebuje zdravilno učinkovino pirlimicin hidroklorid.
How does Pirsue work? 
Kako zdravilo Pirsue deluje?
Both, the teat and the udder should be adequately cleansed and the teat end disinfected before using Pirsue. 
Pred uporabo zdravila Pirsue je treba sesek in vime primerno očistiti, konec seska pa razkužiti.
Skin that has been in contact with Pirsue should be washed and eyes should be flushed with water for 15 minutes immediately after exposure. 
Oči je treba takoj po stiku z raztopino začeti spirati z vodo in nadaljevati s tem 15 minut.
What is Pirsue? 
Kaj je zdravilo Pirsue?
After the last day of treatment with Pirsue, treated cows should not be slaughtered for 23 days. 
Zdravljena krava se ne sme zaklati 23 dni po zadnjem dnevu zdravljenja z zdravilom Pirsue.
After the last day of treatment with Pirsue, milk from treated cows should not be used for 5 days. 
Mleko zdravljenih krav se lahko začne uporabljati po 5 dnevih od zadnjega dneva zdravljenja z zdravilom Pirsue.
Care should, therefore, be taken by the user of the product to avoid contact with the solution. 
Z zdravilom Pirsue je zato treba ravnati previdno, da preprečimo stik z raztopino.
Although the two effects actually have the same results, the first is the most important. 
Čeprav imata ta dva učinka enake rezultate, je prvi najpomembnejši.
Most of its effects are probably due to this structural similarity. 
Večina učinkov je verjetno posledica strukturne podobnosti.
Undesirable effects a. 
Neželeni učinki a.
Children (0-17 years): 
Otroci (0-17 let):
* frequency not known (cannot be estimated from the available data). 
* neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The symptoms of a severe allergic reaction may include: 
Simptomi hude alergijske reakcije lahko vključujejo:
- Coagulation factors (Factor IX) 
- koagulacijski faktorji (faktor IX)
• If you need long-term treatment, since muscle alterations may appear. 
• če potrebujete dolgoročno zdravljenje, saj lahko pride do sprememb mišic.
Please note that these instructions may also apply to medication that you have used before or you can use later. 
To navodilo morda velja tudi za zdravila, ki ste jih uporabljali pred tem, ali jih boste uporabljali kasneje.
This test is negative in primary fibrinolysis. 
Ta test je pri primarni fibrinolizi negativen.
All these events have also been described as part of the natural evolution of SAH, as a result of diagnostic procedures such as angiography. 
Vsi ti dogodki so bili opisani tudi kot del naravnega razvoja SAH kot rezultat diagnostičnih postopkov, kot je angiografija.
If any of these occur while you are taking [Invented name] by mouth, then stop taking [Invented name] and seek immediate medical advice. 
• če imate hematurijo (kri v seču) iz zgornjih sečil,
- Hormonal medication such as oestrogens 
- hormonska zdravila, kot so estrogeni
Not known* 
Neznana*
Do not use a double dose to make up for a forgotten dose but continue to use the vials as usual. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek, temveč z uporabo vial nadaljujte, kot običajno.
Unknown frequency: 
Neznana pogostnost:
Elderly patients and patients with renal failure: 
Starejši bolniki in bolniki z odpovedjo ledvic:
The safety and efficacy of EACA in children aged 0 to 17 years have not been established. 
Varnost in učinkovitost aminokaprojske kisline pri otrocih, starih med 0 in 17 let, nista bili dokazani.
Fertility There are no clinical data on the effects of [invented name] on fertility. 
Plodnost Ni podatkov o vplivu [izmišljeno ime] na plodnost.
Take this leaflet with you. 
S seboj vzemite to navodilo za uporabo.
Therapeutic subgroup: Antihemorrhagics Pharmacotherapeutic group: Antifibrinolytics ATC code: B02AA01. 
Terapevtska podskupina: antihemoragiki Farmakoterapevtska skupina: antifibrinolitiki Oznaka ATC: B02AA01.
Very rare 
Redki zelo redki
When skeletal myopathy occurs, the possibility of damage to the cardiac muscle must also be considered. 
Pri pojavu skeletne miopatije je treba pomisliti tudi na možnost poškodovane srčne mišice.
Plasmin can act on other clotting system components such as factors V and VIII and, in particular, fibrinogen. 
Plazmin lahko deluje na druge sestavine strjevalnega sistema, kot sta faktorja V in VIII, in zlasti na fibrinogen.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicine, even those obtained without a prescription, homeopathic, herbal and other healthrelated products, as it may be necessary to stop the treatment or adjust the dose of one of them. 
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta, homeopatske, zeliščne ali druge zdravilne pripravke, saj bo morda treba zdravljenje prekiniti ali prilagoditi odmerek.
• If you are allergic to aminocaproic acid or to any of the other ingredients of this medicine. 
• če ste alergični na aminokaprojsko kislino ali katero koli sestavino tega zdravila,
The following adverse reactions have been reported from clinical trials, post-authorisation safety studies and from spontaneously-reported cases with the following frequencies: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). 
Med kliničnimi preskušanji, študijami varnosti po odobritvi dovoljenja za promet z zdravilom in spontanimi poročili poročajo o naslednjih neželenih učinkih z naslednjimi pogostnostmi: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do < 1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000).
Allergic reactions may occur uncommonly in patients receiving [Invented name] (in fewer than 1 in 100 patients but more than 1 in 1000 patients). 
Alergijske reakcije se lahko pri bolnikih, ki uporabljajo zdravilo [Izmišljeno ime] pojavijo občasno (pri manj kot 1 od 100 bolnikov, a več kot 1 od 1.000 bolnikov).
This drug must not be administered without a definitive diagnosis and/or laboratory findings indicating hyperfibrinolysis (hyperplasminaemia). 
Zdravila se ne sme uporabiti brez jasne diagnoze in/ali laboratorijskih izvidov, ki kažejo na hiperfibrinolizo (hiperplazminemijo).
Tell your doctor and stop using [invented name] if you experience: 
Obvestite svojega zdravnika in prenehajte uporabljati zdravilo [Izmišljeno ime], če se pojavi kateri koli od naslednjih učinkov:
Carcinogenesis, mutagenesis and fertility disorders: No long-term studies have been conducted in animals to evaluate the carcinogenic or mutagenic potential of aminocaproic acid. 
Karcinogeneza, mutageneza in motnje plodnosti: Pri živalih niso izvedli dolgoročnih študij, da bi ocenili karcinogeni ali mutageni potencial aminokaprojske kisline.
• dizziness, ringing or buzzing in ears, 
• omotica, zvonjenje ali brenčanje v ušesih
• reduction in blood platelets which increases risk of bleeding or bruising 
• zmanjšanje števila krvnih ploščic, kar poveča tveganje za krvavitve ali modrice
• increased pressure in the brain that can result in severe headache, visual disturbance, 
• povečan tlak v možganih, ki lahko povzroči močne glavobole, motnje vida, bruhanje, omotico,
Total dosage should not exceed 18 g/m2 (600 mg/kg) in 24 hours. 
Skupni odmerek ne sme preseči 18 g/m2 (600 mg/kg) v 24 urah.
• difficult or laboured breathing, 
• težko ali oteženo dihanje
In case of overdose with <Aminocaproic acid-containing medicinal products>, tell your doctor or pharmacist immediately, go to the nearest hospital. 
V primeru prevelikega odmerka zdravila <zdravila, ki vsebujejo aminokaprojsko kislino>, o tem takoj obvestite zdravnika ali farmacevta ali pojdite v najbližjo bolnišnico.
The consequences ranged from absence of effects and transient hypotension to acute renal failure resulting in death. 
Posledice segajo od odsotnosti učinkov in prehodne hipotenzije do akutne ledvične odpovedi s posledično smrtjo.
It has been shown that there are evident relationships between the proteolytic activity of plasmin and the system that forms quinines, polypeptides with different biological effects basically related to inflammation and allergy. 
Pokazalo se je, da obstajajo jasna razmerja med proteolitično aktivnostjo plazmina in sistemom, ki tvori kinine, polipeptide z različnimi biološkimi učinki, ki so v osnovi povezani z vnetjem in alergijo.